HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

That Was Fast! ‘30 Minute’ Claim On Lumineux Whitening Strips Goes From NAD Forum To Federal Court

Executive Summary

The National Advertising Division recommended in November that Oral Essentials, Inc. discontinue or modify its “30 minutes to whiter teeth” claim on Lumineux Whitening Strips to avoid implying that a single application will do the deed. Now the company is being targeted with a putative class action in New York’s Eastern District alleging false and misleading advertising.

You may also be interested in...



Australian Teeth Whitener Marketer Frowns On Industry Self-Regulation Referencing US Laws

HiSmile appeals NAD recommendation following review on P&G challenge to discontinue ad claims on its website and in social media videos stating peroxide-containing whitening products are “painful” or cause pain, break down and impact gums and teeth, or “damage” gums.

Lumineux Called For Foul In Teeth Whitening Claim Review For Implying ‘Harm’ From Crest Whitestrips

National Advertising Division recommends Oral Essentials discontinue  claims on packaging that Lumineux strips are "first on the market that are delicious and clinically proven to whiten teeth as well as the leading brand, without the harm associated with bleaches.”

NAD Head Laura Brett On Program Streamlining, Class Action Climate And Mascara Feuds

A Q&A with Laura Brett, four months into her new role as director of the National Advertising Division.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS154288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel